Thérèse Di Paolo Selected Research

Dyskinesias (Dyskinesia)

1/2022	Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.
1/2018	The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
1/2018	Non-human primate models of PD to test novel therapies.
1/2018	Membrane cholesterol removal and replenishment affect rat and monkey brain monoamine transporters.
1/2017	Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
1/2016	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
1/2016	Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
1/2016	mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
12/2015	Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
12/2015	Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thérèse Di Paolo Research Topics

Disease

70	Parkinson Disease (Parkinson's Disease) 12/2021 - 01/2002
54	Dyskinesias (Dyskinesia) 01/2022 - 01/2002
3	Inflammation (Inflammations) 01/2022 - 12/2016
3	Schizophrenia (Dementia Praecox) 06/2010 - 01/2002
3	Parkinsonian Disorders (Parkinsonism) 07/2009 - 08/2005
2	Neuroinflammatory Diseases 12/2021 - 01/2017
1	Gliosis 12/2021
1	Pathologic Processes 01/2019
1	Osteoporosis 12/2016
1	Nausea 01/2016
1	Fatigue 01/2016
1	Dizziness (Lightheadedness) 09/2014
1	Basal Ganglia Diseases (Basal Ganglia Disease) 01/2014
1	Tremor (Tremors) 01/2012
1	Essential Tremor (Essential Tremors) 01/2012
1	Neoplasms (Cancer) 06/2010
1	Central Nervous System Diseases (CNS Diseases) 06/2010

Drug/Important Bio-Agent (IBA)

55	Levodopa (L Dopa)FDA LinkGeneric 01/2022 - 02/2002
37	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 12/2021 - 01/2002
13	Dopamine (Intropin)FDA LinkGeneric 12/2021 - 01/2002
9	Glutamic Acid (Glutamate)FDA Link 01/2017 - 01/2002
9	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2017 - 02/2008
7	N-Methylaspartate (NMDA)IBA 10/2013 - 07/2004
6	SteroidsIBA 01/2019 - 07/2009
6	Pharmaceutical PreparationsIBA 01/2018 - 08/2005
6	Messenger RNA (mRNA)IBA 01/2012 - 02/2002
5	Progesterone FDA LinkGeneric 01/2020 - 07/2009
5	Docosahexaenoic AcidsIBA 12/2019 - 02/2006
5	Serotonin (5 Hydroxytryptamine)IBA 01/2018 - 01/2002
5	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 04/2010 - 07/2004
5	besonprodilIBA 04/2010 - 01/2006
4	Amantadine (Aman)FDA LinkGeneric 01/2018 - 01/2013
4	Selective Estrogen Receptor Modulators (SERM)IBA 12/2016 - 08/2008
4	Cabergoline FDA LinkGeneric 04/2010 - 01/2002
4	Estrogens (Estrogen)FDA Link 05/2009 - 01/2002
3	Dutasteride (Avodart)FDA Link 12/2021 - 10/2015
3	Gonadal Steroid Hormones (Sex Hormones)IBA 12/2021 - 01/2002
3	PlasmalogensIBA 01/2018 - 06/2015
3	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2016 - 05/2004
3	Neuroprotective AgentsIBA 10/2015 - 01/2002
3	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 06/2015 - 02/2006
3	mavoglurantIBA 09/2014 - 05/2011
3	Adenosine (Adenocard)FDA LinkGeneric 01/2014 - 07/2004
3	3- (6- methylpyridin- 2- ylethynyl)cyclohex- 2- enone- O- methyloximeIBA 10/2013 - 07/2011
3	Glutamate Receptors (Glutamate Receptor)IBA 01/2013 - 12/2003
3	Therapeutic UsesIBA 01/2012 - 06/2010
3	Estradiol (Delestrogen)FDA LinkGeneric 03/2011 - 01/2002
3	Kynurenine 3-Monooxygenase (Kynurenine 3 Monooxygenase)IBA 01/2010 - 01/2008
3	BenserazideIBA 06/2009 - 01/2006
3	preproenkephalinIBA 01/2006 - 02/2002
3	GABA-A Receptors (GABA(A) Receptor)IBA 07/2004 - 09/2002
2	AndrogensIBA 01/2021 - 07/2009
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2017 - 01/2010
2	3- (6- p- tolylpyridin- 3- yloxy)- 1- azabicyclo(2.2.2)octaneIBA 01/2016 - 11/2014
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2016 - 11/2014
2	LigandsIBA 12/2015 - 07/2011
2	Ro 25-6981IBA 10/2013 - 06/2009
2	GABA-B ReceptorsIBA 01/2012 - 03/2003
2	Estrogen ReceptorsIBA 09/2011 - 06/2010
2	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 04/2010 - 07/2004
2	Ro 61-8048IBA 01/2010 - 06/2009
2	Excitatory Amino Acid AntagonistsIBA 01/2010 - 01/2002
2	Naltrexone (ReVia)FDA LinkGeneric 01/2010 - 08/2005
1	Metabotropic Glutamate 5 ReceptorIBA 01/2022
1	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA 12/2021
1	salicylhydroxamic acid (SHAM)IBA 12/2021
1	Glial Fibrillary Acidic ProteinIBA 12/2021
1	PPI-1011IBA 01/2018
1	Raloxifene Hydrochloride (Evista)FDA Link 12/2016
1	Serotonin ReceptorsIBA 12/2015
1	pyridineIBA 12/2015
1	Finasteride (Propecia)FDA LinkGeneric 10/2015
1	phosphatidal ethanolaminesIBA 06/2015
1	KetanserinIBA 01/2015
1	6- fluoro- 2- (4- (pyridin- 2- yl)but- 3- yn- 1- yl)imidazo(1,2- a)pyridineIBA 09/2014
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2014
1	Ro 48-8587IBA 10/2013
1	LY 341495IBA 10/2013
1	CGP 39653IBA 10/2013
1	AMPA Receptors (AMPA Receptor)IBA 10/2013
1	safinamideIBA 05/2013
1	Estrogen Receptor alphaIBA 03/2013
1	6-methyl-2-(phenylethynyl)pyridineIBA 03/2013
1	GTP-Binding Proteins (G-Protein)IBA 03/2013
1	Ionotropic Glutamate ReceptorsIBA 01/2013
1	gamma-Aminobutyric Acid (GABA)IBA 01/2012
1	GABA Receptors (GABA Receptor)IBA 01/2012
1	acivicin (AT 125)IBA 05/2011
1	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 05/2011
1	Dihydrotachysterol (AT 10)IBA 06/2010
1	Glycogen Synthase Kinase 3 betaIBA 04/2010
1	Dopamine Agents (Dopaminergic Agents)IBA 04/2010
1	Tuberculin (PPD)IBA 01/2010

Therapy/Procedure

13	Therapeutics 01/2018 - 02/2002
3	Denervation 01/2010 - 05/2004
2	Immunomodulation 01/2020 - 10/2015
2	Drug Therapy (Chemotherapy) 01/2014 - 05/2004
1	Castration 12/2021
1	Operative Surgical Procedures 12/2015
1	Activities of Daily Living (ADL) 06/2011